/PRNewswire/ Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of three lots of Phenylephrine Hydrochloride Injection, USP (10.
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
News provided by
Share this article
Share this article
SUZHOU, China and ROCKVILLE, Md., March 10, 2021 /PRNewswire/ Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical research results of the company s five novel drug candidates have been selected for presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, and have already been published in the meeting s official website. This year s AACR annual meeting will be held in a virtual format on April 27-28 and June 22-24.
Share this article
ATLANTA, March 11, 2021 /PRNewswire/
Juvare, the leader in crisis and emergency management technology, is adding to its support of COVID-19 vaccination efforts with RE-PLAN, a dynamic vaccination POD planning application that helps public health agencies ensure the timely availability of vaccines for communities in need. Using RE-PLAN, planners can identify local capabilities and resources in the context of available infrastructure and demographic data to determine how to move the COVID-19 vaccine from loading docks to arms. With the disparities in death rates and people contracting the coronavirus over the past months – oftentimes in underserved communities – strategic POD planning is of the utmost importance, and there is no time to waste, said Robert Watson, CEO of Juvare. RE-PLAN can help identify those areas with an absence of health care services and resources and mobilize COVID-19 vaccination efforts quickly and efficiently – making the greate
PharmAbcine to Present at AACR Annual Meeting 2021
News provided by
Share this article
Share this article
DAEJEON, South Korea, March 11, 2021 /PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-poster presentation featuring nonclinical data of PMC-309 at American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place virtually over April 10-15 and May 17-21 2021.
Presentation Details
Title: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through blocking the interaction of T cells and myeloid derived suppressor cells (MDSC)
Session category/title: Immunology/Immune Checkpoints